Second opinion: Bad news for Glaxo

Stephen Beard Jul 18, 2007
HTML EMBED:
COPY

Second opinion: Bad news for Glaxo

Stephen Beard Jul 18, 2007
HTML EMBED:
COPY

TEXT OF STORY

Doug Krizner: GlaxoSmithKline’s second-biggest selling drug, Avandia, is in trouble again. German researchers say the diabetes medication doesn’t work, and it could even be harmful. Stephen Beard reports.


Stephen Beard: The German research is pretty damning.

Dr. Bernd Richter of Heinrich Heine University in Dusseldorf found no evidence that Avandia brought any benefit to diabetes patients.

On the other hand, he said, there was plenty of evidence of negative side effects, including weight gain and bone fractures and, more worryingly, an increased risk of heart attack.

Dr. Bernd Richter: We found what is called oedema, that is swelling in the ankles and the lower limbs which could be the first step towards heart failure, was approximately doubled.

His findings are a fresh embarrassment for Glaxo.

A U.S. researcher came to similar conclusions about Avandia earlier in May. Analysts then slashed their earnings forecasts and the Glaxo share price slumped. A Glaxo spokesman dismissed the German findings as inconclusive.

In London, this is Stephen Beard for Marketplace.

We’re here to help you navigate this changed world and economy.

Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.

In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.

Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.